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Abstract 
The importance of interactions between Sox and POU transcription factors in the regulation of gene 
expression is becoming increasingly apparent. Recently, many examples of the involvement of Sox-
POU partnerships in transcription have been discovered, including a partnership between Sox-2 and 
Oct-3. Little is known about the mechanisms by which these factors modulate transcription. To better 
understand the molecular interactions involved, we mapped the location of the transactivation do-
main of Sox-2. This was done in the context of its interaction with Oct-3, as well as its ability to 
transactivate as a fusion protein linked to the DNA-binding domain of Gal4. Both approaches 
demonstrated that Sox-2 contains a transactivation domain in its C-terminal half, containing a serine-
rich region and the C terminus. We also determined that the viral oncoprotein E1a inhibits the ability 
of the Gal4/Sox-2 fusion protein to transactivate, as well as the transcriptional activation mediated 
by the combined action of Sox-2 and Oct-3. In contrast, a mutant form of E1a, unable to bind p300, 
lacks both of these effects. Importantly, we determined that p300 overcomes the inhibitory effects of 
E1a in both assays. Together, these findings suggest that Sox-2 mediates its effects, at least in part, 
through the co-activator p300.  
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Transcription factors belonging to the Sox family contain a conserved HMG1 DNA-binding 
domain that exhibits sequence-specific binding. At least 24 members of the Sox family ex-
pressed in many different cells and tissues have been identified (1). Members of the Sox 
family are further subdivided into subgroups based on the amount of homology outside 
of the HMG domain, as well as identity within the HMG domain. Unlike most transcrip-
tion factors, Sox proteins bind DNA in the minor groove. Hence, Sox factors are able to 
bind DNA in close proximity to transcription factors that bind in the major groove. Indeed, 
interaction and/or cooperation between Sox factors and other transcription factors has 
been observed, including Sox-10 with Tst-1/Oct6/SCIP (2), Sox-11 and Sox-4 with Brn-1 (3), 
and Sox-2 with Oct-3 (4). Sox and POU transcription factors, such as Sox-2 and Oct-3, are 
co-expressed in many different cell types during development (1, 5, 6), as well as in em-
bryonal carcinoma (EC) and embryonic stem cells. Examples of the involvement of Sox-
POU partnerships in transcriptional regulation include transcription of the FGF-4, Osteo-
pontin (OPN), and UTF1 genes in EC cells (4, 7, 8). Recently, the interaction between Sox-2 
and Oct-3 has been linked closely to the transcription of the FGF-4 gene. 
Expression of the FGF-4 gene is controlled by an essential enhancer located in the un-
translated region of the third exon, 3 kilobases downstream of the transcription start site 
(9–11). This distal enhancer contains three important motifs: a POU motif, which binds 
several octamer-binding proteins (11–14); a HMG motif, which binds several members of 
the Sox transcription factor family (3, 15, 16); and a GC box, which binds Sp1 and Sp3 (14). 
The functional importance of these three binding sites for the transcription of the FGF-4 
gene has been demonstrated through site-directed mutagenesis studies (11, 13).2 The fac-
tors that are functionally active at the HMG and POU motifs are Sox-2 and Oct-3, respec-
tively (11, 15, 16). Sox-2 and Oct-3 are co-expressed with the FGF-4 gene in the preimplanta-
tion mouse embryo (1, 17, 18) and in F9 EC and embryonic stem cells (12) but are down-
regulated upon differentiation of these cells (19–21). Furthermore, the HMG and POU sites 
are separated by only three base pairs, and inserting five base pairs between these sites 
results in a loss of enhancer function (4).3 Synergism and physical interaction between Sox-
2 and Oct-3 at their binding sites has been demonstrated (4), indicating that the FGF-4 gene 
is likely to be regulated by the concerted action of Sox-2 and Oct-3. 
The UTF1 and OPN genes are also co-expressed with Sox-2 and Oct-3 in F9 EC and em-
bryonic stem cells, are down-regulated upon differentiation, and contain an HMG motif 
and a POU motif (7, 8). In the UTF1 gene, the HMG and POU motifs are located next to 
one another and approximately 1.8 kilobases downstream of the transcription start site, 
similar to the FGF-4 gene (7). In contrast, these motifs are separated by 48 base pairs and 
are located relatively close to the transcription start site in the OPN gene (8). Both genes 
are regulated by Sox-2 and Oct-3. However, the UTF1 gene is regulated by the synergistic 
action of Sox-2 and Oct-3 (7), whereas Sox-2 represses the Oct-3 activation of the OPN gene 
(8). The repression of the OPN gene by Sox-2 requires the C-terminal region of Sox-2. Pos-
itive regulation of the FGF-4 and UTF1 genes and negative regulation of the OPN gene by 
the combination of Sox-2 and Oct-3 may be attributed to the arrangement of the HMG and 
POU motifs relative to each other, as well as to other transcription factor binding sites. 
These studies illustrate that the effects of Sox factors on transcription are dependent on the 
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context of the gene, but little is known about the mechanisms that Sox factors use to mod-
ulate transcription. 
Recently, it has been reported that the transactivation domain of several Sox family 
members is located in the C-terminal half of the molecule (3, 22–24). However, it is unclear 
whether more than one region of the molecule is needed for transactivation, nor is it clear 
whether the domains involved are dependent on transcription factors that act in concert 
with Sox proteins. Transactivation by many transcription factors requires the action of a 
co-activator. In the context of the HMG and POU sites of the FGF-4 gene, Sox-2 and Oct-3 
activate transcription from a distance. Therefore, co-factors are likely to be involved in 
bridging these proteins to the transcriptional machinery. Interestingly, E1a has been shown 
to repress the Oct-3-mediated expression of the Rex-1 gene (25), as well as the transcription 
of several other genes (reviewed in Ref. 26). In many cases, overexpression of the co-factor 
p300, a ubiquitous protein that can interact directly with E1a, was able to overcome E1a 
inhibition (27–31), indicating a possible role for p300 as a co-activator. 
To advance our understanding of the molecular mechanisms by which Sox-2 acts, sev-
eral questions are addressed in this study. First, which domains of Sox-2 are necessary for 
transactivation? Second, does Sox-2 on its own or in combination with Oct-3 mediate its 
effects through a co-activator? Here, we show that the C-terminal half of Sox-2, including 
its serine-rich domain and extreme C-terminal end, is necessary for transactivation. We 
also demonstrate that E1a inhibits the ability of a Gal4/Sox-2 fusion protein to transactivate, 
as well as the transcriptional activation mediated by Sox-2 and Oct-3. Importantly, we 
demonstrate that the co-activator p300 can recover this inhibition by E1a. These findings 
are the first to implicate p300 in the action of the Sox family of transcription factors. 
 
Experimental Procedures 
 
Cell Culture and Transient Transfections 
HeLa cells were maintained in Dulbecco’s modified Eagle’s medium (Life Technologies, 
Inc.) supplemented with 10% fetal bovine serum (HyClone). HeLa cells were seeded at 5 × 
105 cells per 100-mm dish unless otherwise noted for 24 h prior to transfection. Cells were 
transfected by the calcium phosphate precipitation method, as described previously (11, 
32), incubated with the precipitate for 14–16 h, and refed with Dulbecco’s modified Eagle’s 
medium containing 10% fetal bovine serum. Cells were harvested the following day. Cell 
extracts were prepared, and chloramphenicol acetyltransferase (CAT) and β-galactosidase 
activities were determined, as reported previously (16). The total amount of transfected 
DNA was kept constant by addition of null vectors. To adjust for transfection efficiency, 
all transfections were normalized with either pCH110 (SV40β-gal) (Amersham Pharmacia 
Biotech) or pCMVβ-gal (CLONTECH) as indicated in the figure legends. All transfections 
were performed in duplicate or triplicate with representative transfections shown. Plasmid 
DNA was purified by Qiagen tip-500 columns. 
  
N O W L I N G  E T  A L . ,  J O U R N A L  O F  B I O L O G I C A L  C H E M I S T R Y  2 7 5  (2 0 0 0 ) 
4 
Promoter-Reporter and Sox-2 Deletion Constructs 
The promoter-reporter construct pCatSO3 was constructed as follows: complimentary oli-
gonucleotides (synthesized by the Eppley Cancer Institute Molecular Biology Core Facil-
ity) containing two sets of the Sox-2 and Oct-3 binding sites (in boldface) from the FGF-4 
enhancer region and BglII sites at both ends (5′-GATCTCTTTGTTTGGATGCTAATGGC 
TCTTTGTTTGGATGCTAATGGA-3′) were annealed and ligated to generate multimers. 
These multimers were then ligated into a BglII site upstream of the SV40 promoter of the 
pCat vector (Promega) to generate pCatSO3, which contains a total of six tandem copies of 
the HMG and POU sites. pCMVSox-2 3′ deletion constructs were generated by digesting 
pCMVSox-2 (16) at the NotI site 5′ of the Sox-2 insert and AccI, StyI, or AatII sites within 
the 3′ end of the Sox-2 sequence. The Sox-2 fragments NotI-AccI, NotI-StyI, and NotI-AatII 
were isolated and ligated into pCMVΔSox-2N/X vector (pCMVSox-2 digested at the NotI 
and XhoI sites flanking the Sox-2 sequence and isolated), to generate pCMVSox-21–293, 
pCMVSox-21–242, and pCMVSox-21–202, respectively. pCMVSox-21–180 (pCMVNP2) has been 
described previously (16). 
Sox-2 was isolated from pCMVSox-2 by digesting with NotI and XhoI and then cloned 
into pCR-Script Amp SK(+) (Stratagene) to generate pCRSox-2. This construct was then 
used to generate additional Sox-2 deletions. pCRSox-2Δ177–293 was generated by performing 
PCR with pCRSox-2 and the 3′ primer 177L (5′-CTGCTCCTGCATCATGCTGTAGCTG-3′) 
and the 5′ primer 293U (5′-CGACTGCACATGGCCCAGCTC-3′). This amplified the entire 
plasmid excluding the region of Sox-2 of base pairs 537–879 (amino acids 177–293). The 
PCR product was then digested with DpnI, which will digest methylated DNA destroying 
the parental plasmid, ligated, and transformed into bacteria. Similarly, pCRSox-2 and ei-
ther the primer pair of 3′ primer 45L (5′-CCTCTTGACGCGTTCCGGGCT-3′) and 5′ primer 
116U (5′-ATCCGGAAAACCAAGACGCTCATGAAG-3′) or the primer pair of 3′ primer 
207L (5′-CTGCAGGGCGCTGACGTCGTA-3′) and 5′ primer 254U (5′-GATCCCGTGGTTA 
CCTCTTCCTCCCA-3′) were used in PCRs to generate pCRSox-2Δ45–116 and pCRSox-2Δ207–
254, respectively. pCRSox-2Δ45–116 excludes the region of Sox-2 of base pairs 135–348 (amino 
acids 45–116) and pCRSox-2Δ207–254 excludes the region of Sox-2 of base pairs 621–762 
(amino acids 207–254). In the case of the Δ45–116 and Δ207–254 constructs, an additional 
three base pairs were added to the 5′ end of the 5′ primers, which, after PCR and ligation, 
generated a BamHI site that was used for screening. After confirmation by sequencing, the 
Sox-2 deletions were isolated following NotI-XhoI digestion and ligated into pCMVΔSox-
2N/X. 
The 5′ end of Sox-2 was tagged with the Flag epitope as follows. A 5′ primer (5′-
CGCGCGGGTACCGCCACCATGGACTACAAGGACGACGATGACATGTATAACATG 
ATGGAGACG-3′) containing a KpnI site, a Kozac sequence, the Flag sequence, and 24 base 
pairs of the 5′ Sox-2 sequence and the 3′ primer 45L (described above) were used in a PCR 
with pCMVSox-2 as template. The resulting product was digested with KpnI and HindIII 
and ligated into pCMVΔSox-2K/H vector (pCMVSox-2 digested with KpnI and HindIII and 
isolated), generating pCMVFlagSox-2. The same method was used to insert the Flag se-
quence into the pCMVSox-2 deletion constructs. Sequencing confirmed that all constructs 
contained the Flag sequence in-frame with Sox-2. A GFPSox-2 expression vector was con-
structed by ligating a SacI-KpnI Sox-2 fragment from pCRSox-2 into the SacI-KpnI sites of 
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pEGFP-C1 (CLONTECH), fusing green fluorescent protein (GFP) in-frame to the N termi-
nus of Sox-2. Positive clones were verified by sequencing. 
Other plasmids utilized included pCMVOct-3 (11); Gal4/Sox-11 C3, obtained from Mi-
chael Wegner (3); pCMVOct-1, obtained from Clinton Jones (University of Nebraska, Lin-
coln, NE); pCMV12S E1a and pCMV12S E1aΔ2–36 (mE1a), a mutant E1a unable to bind 
p300, obtained from Joseph Nevins (33); and pCMVp300 and pCMVp300del30, a mutant 
p300 unable to bind E1a, obtained from David Livingston (34). 
 
Gal4 Constructs 
Gal4/Sox-2 fusions were constructed by ligating PCR-generated Sox-2 fragments into the 
EcoRI and HindIII sites of the SV40Gal4 fusion vector, pM3, obtained from Ivan Sadowski 
(35). The following primers were used in PCRs to generate the Sox-2 fragments indicated: 
Sox-2121–319, 121U (5′-CCGTCAATGAATTCTCATGAAGAAGGATAAGTACACG-3′) 
and 319L (5′-TATTTGAAGCTTCTCACATGTGCGACAGGGG-3′); Sox-2206–319, 206U 
(5′-GTCAATGAATTCTGCAGTACAACTCCATGACCAGC-3′) and 319L; Sox-2206–291, 
206U and 291L (5′-TATTTGAAGCTTGGGCGCAGCGGGCT-3′); Sox-2206–260, 206U and 
260L (5′-TATTTGAAGCTTGGAGGAAGAGGTAACCACGGG-3′); Sox-2291–319, 291L 
(5′-GTCAATGAATTCCCAGTAGACTGCACATGGCC-3′) and 319L. All resulting con-
structs were sequenced and determined to be in frame with Gal4 and named as indicated 
in figure 3A. These constructs were co-transfected with pG5EC obtained from Ivan Sa-
dowski (35). pG5EC contains five Gal4 DNA-binding sites upstream of the TATA box from 
the adenovirus E1b gene driving the CAT reporter gene. BglII-HindIII fragments from pM3 
and Gal4/Sox-2206–319 were ligated into the BglII and HindIII sites of pCMV5 (36) to gen-
erate the plasmids CMVGal4 and CMVGal4/Sox-2206–319, respectively. 
 
Western Blotting 
HeLa cells were transfected as described above. In each case, CMVβ-gal was co-transfected 
with the plasmids indicated in the figure legends and used to normalize for differences in 
transfection efficiency. Whole cell extracts were prepared after transfection as follows. 
Cells were washed twice with 5 ml of cold phosphate-buffered saline, harvested into 1 ml 
of cold phosphate-buffered saline, and centrifuged. The cell pellets were resuspended in 
lysis buffer (10 mM Tris, pH 7.4–8.0, 150 mM NaCl, 1% Triton X-100, various protease and 
phosphatase inhibitors) and incubated on ice for 30 min. Following centrifugation, the su-
pernatant was transferred to a new tube, aliquoted, and stored at –80°C. Extracts were 
assayed for β-galactosidase activity, normalized, and diluted in 4× sample buffer (250 mM 
Tris-HCl, pH 6.8, 8% w/v SDS, 40% glycerol, 200 mM dithiothreitol, 0.4% (w/v) bromphe-
nol blue), heated to 95–100°C for 5 min, and loaded onto a Tris-glycine gel. Gels were sub-
jected to electrophoresis in running buffer (25 mM Tris, 0.2 M glycine, and 0.1% SDS). 
Proteins were then transferred to polyvinylidene difluoride membrane (Immobilon-P, Mil-
lipore) in transfer buffer (25 mM Tris, 0.2 M glycine, 20% methanol) and membranes were 
blocked in a 3% bovine serum albumin solution. For detection of the Gal4 fusion proteins, 
membranes were incubated with an anti-Gal4 DNA-binding domain (DBD) polyclonal an-
tibody (Upstate Biotechnology, Lake Placid, New York) diluted 1:2000 in blocking buffer 
+0.1% Tween-20, washed in TBS/T (Tris buffered saline, 0.1% Tween-20), and incubated 
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with an alkaline phosphatase-conjugated secondary antibody (Pierce) diluted 1:10 000 in 
TBS/T. For detection of the Flag fusion proteins, membranes were incubated with an anti-
Flag M2 monoclonal antibody (Sigma) diluted 1:2000 in TBS/T, washed in TBS/T, and in-
cubated with an alkaline phosphatase-conjugated secondary antibody (Pierce) diluted 
1:2000 in TBS/T. Proteins were detected using the enhanced chemifluorescence (ECF) kit 
(Amersham Pharmacia Biotech) and scanned on a Storm phosphorimager (Molecular Dy-
namics). Quantitation was performed using the ImageQuant analysis software (Molecular 
Dynamics). All Western blots were performed in duplicate or triplicate, with representa-
tive Western blots shown. 
 
Results 
 
Mapping of the Sox-2 Transactivation Domains Using the Gal4 System 
The HMG and POU sites located in the enhancer of the FGF-4 gene are crucial for tran-
scription (9, 11, 13). Furthermore, overexpression studies have shown that Oct-3 on its own 
can stimulate transcription of promoter-reporter constructs containing the HMG and POU 
sites of the FGF-4 enhancer (11) and that the addition of Sox-2 results in a synergistic stim-
ulation of transcription (15). Although the transactivation domains of Oct-3 have been 
mapped (37–40) and Sox-2 and Oct-3 have been shown to physically interact (4), it is un-
clear how these factors cooperate to stimulate transcription. Therefore, to advance our un-
derstanding of this partnership, we set out to investigate the molecular mechanisms by 
which Sox-2 acts by mapping the transactivation domain of Sox-2. Previous studies 
demonstrated that the N-terminal region of Sox-2 (Sox-21–180) contains the DNA-binding 
domain (15, 16). These studies and others (3, 22, 23) indicate that the transactivation do-
main of Sox-2 is likely to be located in the C-terminal half of the protein. 
To map the domains of Sox-2 transactivating activity, a series of fusion proteins con-
taining the DBD of Gal4 and various regions of Sox-2 was constructed. Gal4 fusion proteins 
have been used widely to identify transactivation domains of transcription factors. In these 
studies, various Sox-2 C-terminal regions were cloned into pM3, a Gal4 DBD expression 
vector (Fig. 1A). These Gal4/Sox-2 fusion constructs were cotransfected into HeLa cells 
with the promoter-reporter CAT construct pG5EC, containing five copies of the Gal4 bind-
ing site. The region from just C-terminal of the HMG domain to the C-terminal end (amino 
acids 121–319) exhibited maximum transactivation at the concentration indicated (fig. 1B). 
However, the region from the serine-rich domain to the C-terminal end, amino acids 206–
319, also contains considerable transactivation potential (fig. 1B). Constructs containing 
only the serine-rich domain (Gal4/Sox-2206–291 and Gal4/Sox-2206–260) or the last 28 amino ac-
ids of the C terminus (Gal4/Sox-2291–319) failed to transactivate, whereas constructs contain-
ing both of these domains (Gal4/Sox-2121–319 and Gal4/Sox-2206–319) were able to transactivate. 
This suggests that both the serine-rich domain (amino acids 206–260) and the C-terminal 
end (amino acids 260–319) are necessary for transactivation. A Gal4/Sox-11 construct 
(Gal4/Sox-11 C3) (3) served as a positive control and was able to transactivate in all of the 
Gal4 experiments (data not shown). 
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Figure 1. Mapping of the transactivation domain of Sox-2. A, schematic representation of the 
fusions between the Gal4 DBD (Gal4) driven by a SV40 promoter and various regions of 
murine Sox-2 as described under “Experimental Procedures.” Subscript numbers indicate 
the amino acids of Sox-2 contained in the fusion proteins. B, transfection into HeLa cells 
with 2 μg of the promoter-reporter construct pG5EC alone or in combination with either 
5 μg of pM3 or 1 μg of the indicated Gal4/Sox-2 plasmids. C, expression of Gal4 fusion 
proteins in transfected HeLa cells. Extracts from transfected cells were subjected to West-
ern blot analysis with an antibody to the Gal4 DBD. Fusion proteins were detected by 
ECF. The predicted sizes of the Gal4/Sox-2 fusion proteins are as follows: 121–319, 38 kDa; 
206–319, 28.6 kDa; 206–291, 25.5 kDa; 206–260, 22.1 kDa; 291–319, 19.3 kDa; and Gal4 
(pM3), 16.2 kDa. Molecular mass markers (in kDa) are shown on the left. D, transfection 
into HeLa cells with 2 μg of pG5EC alone or in combination with either 5 μg of pM3 or 1 
μg of Gal4/Sox-2206–319 plus 5 μg of the Gal4/Sox-2 plasmids indicated. pCMVb-gal was 
used for normalization in all transfections. A constant amount of total DNA was achieved 
by adding a null SV40-expressing plasmid. Results of transfections are presented as fold 
induction over the expression of pG5EC alone. pG5EC is a promoter-reporter plasmid 
containing five copies of the Gal4 DNA-binding site upstream of a SV40 promoter driving 
the CAT gene, and pM3 is a Gal4 DBD expression vector driven by a SV40 promoter. 
 
Western blot analysis demonstrated that the Gal4/Sox-2 fusion proteins were expressed 
(fig. 1C). Although a number of nonspecific bands were detected due to the amount of 
protein loaded, it is evident that each of the Gal4/Sox-2 fusion proteins was expressed at 
the predicted size (see the legend to fig. 1). The slight differences in expression levels do 
not correlate with transactivation levels and therefore do not explain the failure of several 
Gal4/Sox-2 fusion proteins (Gal4/Sox-2206–291, Gal4/Sox-2206–260, and Gal4/Sox-2291–319) to 
transactivate (compare fig. 1B and fig. 1C). Furthermore, each of the inactive constructs, as 
well as Gal4, when titrated against Gal4/Sox-2206–319 in co-transfection assays, drastically 
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inhibited the transactivation observed with Gal4/Sox-2206–319 (fig. 1D and data not shown). 
Together, these results argue strongly that the inactive constructs are expressed and are 
able to compete for binding to the Gal4 binding sites. 
 
Deletion Mapping of the Sox-2 Transactivation Domains 
To map the transactivation domains of Sox-2 in the context of its synergistic stimulation of 
transcription in conjunction with Oct-3, HeLa cells were utilized because they do not con-
tain endogenous Sox-2 or Oct-3. In addition, a promoter-reporter construct, pCatSO3, was 
designed that contains six copies of the HMG and POU motifs from the FGF-4 enhancer 
upstream of a SV40 promoter driving the CAT gene (fig. 2A). In HeLa cells, pCatSO3 has 
minimal activity on its own and relatively little activity when co-transfected with either a 
Sox-2 or an Oct-3 expression vector (fig. 2B). In contrast, a substantial stimulation was ob-
served when pCatSO3 was co-transfected with both Sox-2 and Oct-3 expression vectors 
(fig. 2, B and C), illustrating the synergistic interaction of Sox-2 and Oct-3. Additionally, a 
truncated Sox-2 protein, Sox-21–180, which retains its DNA-binding and Oct-3 interacting 
domain, did not stimulate pCatSO3 on its own but did induce some stimulation in con-
junction with Oct-3. However, the stimulation observed with Sox-21–180 and Oct-3 was sig-
nificantly less than that observed with full-length Sox-2 (Sox-21–319) and Oct-3 (fig. 2, B and 
C). This latter finding suggests that Sox-2 transactivation is dependent, at least in part, on 
its C-terminal region. 
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Figure 2. Expression and activation of the promoter-reporter construct pCatSO3 in HeLa cells. A, 
physical map showing the construction of the pCatSO3 vector. Three copies of annealed 
oligonucleotides containing two sets of the HMG and POU sites of the FGF-4 enhancer 
were ligated into a BglII site upstream of the SV40 promoter driving the CAT reporter 
gene as described under “Experimental Procedures.” B, cells were transfected with 5 μg 
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of the parent vector pCat alone or in combination with 1 μg of the CMV-expressing plas-
mids indicated or with 5 μg of pCatSO3 alone or in combination with 1 μg of the CMV-
expressing plasmids indicated. C, cells were transfected with 5 μg of pCatSO3 alone or in 
combination with the amount of CMV-expressing plasmids indicated. pCH110 (SV40β-
gal) was used for normalization in all transfections. A constant amount of total DNA was 
achieved by adding the null CMV vector, pCMV5. Subscript numbers indicate the amino 
acids of Sox-2 contained in the construct. Results of transfections are presented as fold 
induction over the expression of pCat (open bars) or pCatSO3 (solid bars) alone. 
 
To further map the transactivation domains of Sox-2 in the context of the HMG and 
POU motifs of the FGF-4 enhancer, a series of CMV expression vectors containing Sox-2 C-
terminal deletions was constructed (fig. 3A). These constructs were co-transfected with 
pCatSO3 into HeLa cells with or without Oct-3. None of the Sox-2 deletions were able to 
transactivate on their own, but all were able to stimulate transcription in conjunction with 
Oct-3 (fig. 3B). However, the stimulation observed by Oct-3 and the Sox-2 deletion mutants 
was reduced significantly compared with the stimulation with Oct-3 and Sox-21–319 (fig. 3B). 
In all cases, the stimulation was reduced approximately to the level of that observed with 
the shortest Sox-2 construct, Sox-21–180, which indicated that deleting even a small region 
from the C terminus (amino acids 293–319) results in a significant reduction in transacti-
vation. However, because the truncated proteins have little activity on their own compared 
with Sox-21–319 (fig. 3B), the transactivation domain of Sox-2 is not likely to be located in the 
N-terminal region. To determine whether regions other than the extreme C terminus 
(amino acids 293–319) were necessary for transactivation, Sox-2 mutants containing inter-
nal deletions of amino acids 207–254 (Sox-2Δ207–254) or 177–293 (Sox-2Δ177–293) were con-
structed. Transfections with Oct-3 and these Sox-2 mutants resulted in decreased 
stimulation of pCatSO3 (fig. 3C). These results indicate that regions other than the extreme 
C terminus are necessary for transactivation. A construct containing a deletion of the HMG 
domain (Sox-2Δ45–116) results in no additional stimulation above that seen with Oct-3 alone. 
This was expected because the HMG domain is necessary for binding to the HMG motif 
(15, 16) and for interaction with Oct-3 (4). 
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Figure 3. Deletion mapping of the Sox-2 transactivation domain. A, schematic representation 
of Sox-2 and the Sox-2 deletion cDNAs. All deletions were ligated into a CMV expression 
plasmid as described under “Experimental Procedures.” B, HeLa cells were transfected 
with 5 μg of pCatSO3 alone or in combination with 1 μg of the CMV-expressing plasmids 
indicated. C, HeLa cells were transfected with 5 μg of pCatSO3 alone or in combination 
with 1 μg of the CMV-expressing plasmids indicated. pCH110 or CMVb-gal was used for 
normalization. A constant amount of total DNA was achieved by adding the null CMV-
expressing vector, pCMV5. Results of transfections are presented as fold induction over 
the expression of pCatSO3 alone. D, expression of FlagSox-2 fusion protein and FlagSox-
2 deletion fusion proteins in transfected cells. Extracts from transfected HeLa cells were 
subjected to Western blot analysis with an antibody to Flag. Fusion proteins were detected 
by ECF. The predicted sizes of the FlagSox-2 proteins are as follows: 1–319, 37.7 kDa; 1–
293, 34.8 kDa; 1–242, 29.2 kDa; 1–202, 24.8 kDa; 1–180, 22.4 kDa; D207–254, 32.5 kDa; and 
D45–116, 29.9 kDa. Molecular mass markers (in kDa) are shown on the left. 
 
To ensure that these Sox-2 deletions were being expressed, the Flag sequence was in-
serted at the N terminus of Sox-21–319 and all of the Sox-2 deletion constructs. Extracts from 
cells transfected with these constructs were subjected to Western blot analysis with anti-
Flag M2 antibody. Protein expression from the FlagSox-2 deletion constructs at the pre-
dicted sizes was observed readily (fig. 3D). Although small differences in the expression 
levels from several of these constructs was observed, their protein expression levels do not 
account for their activity levels. Furthermore, the Flag epitope did not alter the function of 
these constructs because all of the FlagSox-2 deletion constructs were able to stimulate 
transcription in conjunction with Oct-3 (data not shown) similar to that observed with the 
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untagged deletion constructs (fig. 3B). Because all of the above Sox-2 deletion constructs 
contain the DNA-binding (HMG) and Oct-3 interaction domain, the observed stimulation 
in conjunction with Oct-3 may be due to a stabilization of Oct-3 binding (see under “Dis-
cussion”). 
 
p300 Recovers E1a Inhibition of pCatSO3 and Stimulates the Activity of Sox-2/Oct-3 
Previous results have shown that E1a inhibits the synergistic activation of the Rex-1 gene 
by Rox-1 and Oct-3 (25). The Rox-1 and POU sites are adjacent to each other on the Rex-1 
promoter, similar to the HMG and POU sites of the FGF-4 enhancer. Furthermore, E1a 
reduces the expression of FGF-4 promoter-reporter constructs containing the HMG and 
POU motifs that bind Sox-2 and Oct-3, respectively.4 Therefore, the effect of E1a on Sox-
2/Oct-3 activation of pCatSO3 was examined. A dose-dependent decrease of transcrip-
tional activity was observed (fig. 4A). In contrast, a mutant form of E1a (mE1a) that lacks 
amino acids 2–36 and that does not bind p300 had little effect on Sox-2/Oct-3 activation of 
pCatSO3 (fig. 4A). Control transfections with pCatSO3, pCMVβ-gal, or pCMVCat demon-
strated that neither E1a nor mE1a has any effect on the basal expression of pCatSO3 or on 
the expression of the CMV promoter, which drives several reporter genes (data not shown, 
also see fig. 5C). This suggested a role for p300 in mediating the effects of Sox-2/Oct-3. To 
examine this possibility, HeLa cells were transfected with pCatSO3 and with Oct-3, Sox-2, 
and p300 expression vectors with or without an E1a expression vector. We observed that 
p300 was able to recover, in a dose-dependent manner, the inhibition by E1a (fig. 4B). Ad-
ditionally, p300 seemed to further stimulate the transcription of pCatSO3 by Sox-2 and 
Oct-3 (fig. 4B). Interestingly, a p300 construct mutant for binding to E1a (p300del30) also 
was able to recover the E1a inhibition (fig. 4B). Extracts from cells transfected as above, but 
with the FlagSox-2 construct, were subjected to Western blot analysis with anti-Flag M2 
antibody. Neither E1a nor p300 alone or in combination affected the level of FlagSox-2 
protein (fig. 4C), and the Flag epitope did not alter the function of this construct (data not 
shown). These results indicate that p300 can mediate the transcriptional effects of Sox-2 
and Oct-3. 
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Figure 4. Effects of E1a and p300 on activation of pCatSO3 by Sox-2 and Oct-3. A, transfection 
of HeLa cells with 5 μg of pCatSO3 alone or in combination with 1 μg each of the CMV 
expression plasmids Sox-2 and Oct-3 plus increasing amounts of CMV plasmids express-
ing 12S E1a (E1a) or 12S E1aΔ2–36 (mE1a), as indicated. B, transfection of HeLa cells with 
5 μg of pCatSO3 alone or in combination with 1 μg each of the CMV-expressing plasmids 
Sox-2 and Oct-3 along with the amount of CMV-expressing plasmids indicated. A con-
stant amount of total DNA was achieved by adding the null CMV vector, pCMV5. Results 
are presented as fold induction over the expression of pCatSO3 alone. C, expression of 
FlagSox-2 fusion protein in HeLa cells transfected with FlagSox-2 alone or in combination 
with E1a, mE1a, and/or p300 CMV expression vectors. Extracts from transfected cells were 
subjected to Western blot analysis with an antibody to Flag. Fusion proteins were detected 
by ECF, and the resulting bands were quantitated. Expression values, relative to the ex-
pression of Sox-2 only, are shown below each lane. pCH110 or CMVb-gal was used for 
normalization. mE1a is a plasmid expressing a mutant E1a unable to bind p300. 
 
To extend these findings, we examined the effect of E1a on the ability of Gal4/Sox-2 to 
transactivate and whether p300 is mediating the transcriptional effects of Sox-2. For these 
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studies, a Gal4/Sox-2 fusion construct driven by the CMV promoter was utilized. We ob-
served that E1a, but not mE1a, inhibits the transactivation of the Gal4/Sox-2206–319 con-
struct, which contains the serine-rich domain and C-terminal end (fig. 5A). As with the 
pCatSO3 construct, p300 was able to recover the E1a inhibition of Gal4/Sox-2206–319 transac-
tivation, as well as further stimulate the transactivation of Gal4/Sox-2206–319 (fig. 5B). Fur-
thermore, we demonstrated that E1a, mE1a, and p300 had no effect on the basal expression 
of the promoter-reporter construct, pG5EC (data not shown). Importantly, E1a did not 
have a significant effect on the protein levels of Gal4 or Gal4/ Sox-2206–319 driven by the CMV 
promoter (fig. 5C). Therefore, a reduction in Gal4/Sox-2206–319 fusion protein levels does not 
account for the substantial reduction in Sox-2 transactivation by E1a (compare fig. 5B to 
fig. 5C). As an added control, the effect of E1a on the nuclear localization of Sox-2 was 
examined by transfecting a GFPSox-2 expression vector alone or in combination with E1a 
into HeLa cells. We determined that E1a does not affect the localization of Sox-2 into the 
nucleus (fig. 6), nor does E1a affect GFP itself (data not shown). This indicates that E1a is 
not inhibiting the transactivation of Sox-2 by preventing Sox-2 from localizing to the nu-
cleus. Together, these results suggest strongly that Sox-2 transactivation is mediated by the 
co-activator p300. 
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Figure 5. Effects of E1a and p300 on Sox-2 transactivation. A, transfection of HeLa cells with 
2 μg of pG5EC alone or in combination with 1 μg of CMVGal4 or 1 μg of CMVGal4/Sox-
2206–319 (G4/S2206–319) expression vectors and increasing amounts of the CMV plasmids ex-
pressing 12S E1a (E1a) or 12S E1aΔ2–36 (mE1a) as indicated. B, transfection of HeLa cells 
with CMVGal4/Sox-2206–319 (G4/S2206–319) alone or in combination with 0.25 μg of CMV plas-
mid expressing E1a and increasing amounts of the CMV plasmid expressing p300 indi-
cated. A constant amount of total DNA was achieved by adding the null CMV vector, 
pCMV5. Results are presented as fold induction over the expression of pG5EC alone. C, 
expression of Gal4 protein and G4/S2206–319 fusion protein in HeLa cells transfected with 
Gal4 or G4/S2206–319 alone or in combination with CMV plasmids expressing E1a and/or 
p300. Extracts from transfected cells were subjected to Western blot analysis with anti-
Gal4 DBD antibody. Fusion proteins were detected by ECF, and the resulting bands were 
quantitated. Expression values for Gal4 in the presence of E1a or p300, relative to the ex-
pression of Gal4 in the absence of E1a or p300 (*) and expression values for G4/S2206–319 in 
the presence of E1a and/or p300, relative to the expression of G4/S2206–319 in the absence of 
E1a or p300 (#), are shown below each lane. pCMVβ-gal was used for normalization in all 
transfections. mE1a is a plasmid expressing a mutant E1a unable to bind p300. 
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Figure 6. Effect of E1a on the nuclear localization of Sox-2. HeLa cells (105) were transfected 
with GFPSox-2 alone or in combination with CMV12S E1a. A representative field from 
each transfected plate is shown. A and B, cells transfected with 1 μg of GFPSox-2. C and 
D, cells transfected with 1 μg of GFPSox-2 and 0.25 μg of CMV12S E1a. Photomicrographs 
were taken under brightfield (A and C) and fluorescence (B and D). 
 
Discussion 
 
The Transactivation Domains of Sox-2 Include a Serine-rich Domain and the Extreme C-
terminal End 
The transactivation domains of several Sox factors, including Sox-11, 4, and 9, have been 
identified recently (3, 22, 23). In this study, we have mapped the location of the transacti-
vation domain of the murine Sox-2 gene product in the context of two experimental pro-
moters, including one that responds to the synergistic action of Sox-2 and Oct-3. For each 
of the Sox factors studied thus far, including Sox-2, the transactivation domain has been 
mapped to the C-terminal region. This is interesting, given that there is little sequence ho-
mology between the C-terminal region of Sox-2 and the Sox factors mentioned above. 
However, each of these Sox family members contains a serine-rich domain in its C-terminal 
region, which is necessary for transactivation (Figs. 1B and 3, B and C; Refs. 3, 22, and 23). 
Studies reported here using Gal4 fusion proteins illustrate that the Sox-2 region of amino 
acids 206–319 is able to transactivate when fused to the DNA-binding domain of Gal4. 
Although the region of amino acids 260–291 was not tested in these Gal4 constructs, it is 
unlikely that this region by itself can transactivate based on the results with the Sox-2 de-
letion, Sox-2Δ207–254. This deletion construct includes amino acids 260–291 but lacks the serine-
rich domain and exhibits significantly reduced transactivation, demonstrating the need for 
both the serine-rich domain and the C-terminal end for transactivation. Additional studies 
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using C-terminal deletions of Sox-2 demonstrate that the region of amino acids 121–319 is 
necessary for maximal synergistic transactivation in conjunction with Oct-3. However, 
considerable transactivation potential resides in the region containing the serine-rich do-
main and the C-terminal end (amino acids 206–319). These results further demonstrate the 
need for both the serine-rich domain and C-terminal end for transactivation. 
The necessity of the last 28 amino acids for Sox-2 transactivation was surprising when 
compared with the results of experiments with fusion proteins of the Gal4 DBD and the 
chicken homolog of Sox-2, cSox-2. Sox-2 and cSox-2 are 93% identical within the last 28 
amino acids. However, our Gal4/Sox-2 construct containing a deletion of the last 28 amino 
acids (Gal4/Sox-2206–291) was unable to transactivate, whereas a Gal4/cSox-2 construct con-
taining a deletion of the last 35 amino acids was reported to transactivate (24). This may be 
attributed to differences in the cell types utilized or to evolutionary differences between 
murine and chicken Sox-2. 
Although there was a pronounced reduction in stimulation of transcription when the 
transactivation domain of Sox-2 was deleted, some synergistic transcriptional stimulation 
with Oct-3 and the truncated Sox-2 proteins was observed. Given that the DNA-binding 
domains of Sox-2 and Oct-3 have been shown to bind cooperatively with one another in 
vitro (4), it is likely that Sox-2 lacking the C-terminal transactivation domain can bind to 
the HMG motif and interact with Oct-3 to stabilize its binding to the neighboring POU 
motif. In this regard, stabilization of DNA binding by transcription factors has been ob-
served for several other homeodomain proteins (41–44). Thus, cooperative binding of Sox-
2 and Oct-3 to DNA may be partly responsible for the synergistic stimulation of transcrip-
tion by these two transcription factors. 
 
p300 Is a Candidate Co-activator for Sox-2 regulated Transcription 
E1a is a viral protein known to influence the expression of many genes. E1a-like activity 
has been found in several cell types, but the endogenous protein(s) involved has yet to be 
identified. E1a has been shown to interact with several cellular proteins, including p300 
and Rb, and to activate or repress the transcription of several genes (reviewed in ref. 26). 
For example, E1a inhibits Rex-1 promoter-reporter gene constructs in EC cells (25). The 
Rex-1 promoter contains two positive regulatory elements, a POU motif and a novel motif, 
necessary for Rex-1 gene transcription in EC cells. Positive regulation of the Rex-1 promoter 
requires binding of Oct-3 to the POU motif and binding of a protein designated Rox-1 to 
the novel (Rox) motif (25). Because the Rox and POU motifs are juxtaposed in a manner 
virtually identical to the HMG and POU motifs in the FGF-4 enhancer and because in EC 
cells E1a reduces the expression of a FGF-4 promoter-reporter construct containing the 
HMG and POU motifs,4 we initially examined whether E1a could affect the stimulation of 
transcription mediated by Sox-2 and Oct-3. When expression vectors for E1a, Sox-2, and 
Oct-3 were co-transfected with the promoter-reporter gene construct pCatSO3, containing 
the HMG and POU sites, a dose-dependent inhibition of transcription was induced by E1a, 
even at extremely low concentrations of the E1a expression vector. These results suggest 
that E1a is inhibiting transcription either by directly interacting with Sox-2 and/or Oct-3 or 
by sequestering a co-activator that interacts with Sox-2 and/or Oct-3. It has been previously 
shown that E1a interacts directly with p300 (45, 46), and we determined here that a mutant 
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form of E1a that cannot bind p300 (mE1a) does not inhibit expression of pCatSO3 by Sox-
2 and Oct-3. Therefore, our findings argue strongly that the effects of E1a are unlikely to 
be due to a direct interaction between E1a and Sox-2 and/or Oct-3. Instead, E1a is likely to 
be interacting with a co-activator of Sox-2 and/or Oct-3 to inhibit transcription. 
Because mE1a does not inhibit Sox-2/Oct-3 stimulation of transcription, we examined a 
possible role for p300 in mediating the effects of Sox-2/Oct-3. p300 is a large nuclear protein 
found in most mammalian cells. It interacts with many different transcription factors (re-
viewed in ref. 47) and with the basal transcriptional machinery (48). However, p300 does 
not appear to bind directly to DNA. Therefore, p300 is thought to elicit its effects on tran-
scription by acting as a bridging factor between the DNA-binding transcription factors and 
the basal transcriptional machinery. Overexpression of p300 has been shown to overcome 
the inhibitory effects of E1a on the prolactin, p53, β-myosin heavy chain, HER-2/neu, and col-
lagenase promoters (27–31), suggesting that p300 plays a role in the transcription of these 
genes. Similarly, the work reported in this study argues that p300 is involved in the stim-
ulation of transcription brought about by Sox-2/Oct-3. First, overexpression of p300 recov-
ers the E1a inhibition of pCatSO3 transcription induced by Sox-2 and Oct-3. Second, in the 
absence of E1a, overexpression of p300 seemed to further stimulate the transcriptional syn-
ergism of Sox-2 and Oct-3. Third, and importantly, a p300 mutant (p300del30), which is 
unable to bind E1a, was also able to overcome the E1a inhibition of Sox-2/Oct-3 transcrip-
tional activation. This last result argues that p300 is not sequestering E1a and preventing 
E1a from interacting with and inhibiting another co-factor required for Sox-2/Oct-3 activa-
tion. Instead, this result argues that E1a interacts directly with p300 and prevents p300 
from stimulating transcription through Sox-2/Oct-3. 
We also examined whether E1a affects the ability of Gal4/Sox-2 to transactivate. As ob-
served with Sox-2/Oct-3 activation of pCatSO3, E1a, but not mE1a, inhibited Gal4/Sox-2206–319 
activation of the promoter-reporter construct pG5EC. Furthermore, p300 was able to res-
cue the E1a inhibition of Gal4/Sox-2206–319 activation and further stimulate the transactiva-
tion of Gal4/Sox-2206–319. Together, these studies provide strong evidence that p300 may be 
a co-activator of Sox-2/Oct-3 synergistic activation through the transactivation domain of 
Sox-2. In conclusion, the studies reported here describe several important findings. First, 
two different experimental promoters were used to map the location of the transactivation 
domain of Sox-2. Second, we determined that the co-activator p300 can mediate the effects 
of Sox-2. To our knowledge, this is the first report of a co-activator that mediates the action 
of a member of the Sox family of transcription factors, a family composed of at least 24 
members. These findings raise several important questions that warrant further study, 
namely, does p300 directly interact with Sox-2? can p300 also mediate the effects of Oct-3? 
and does p300 mediate the effects of other members of the Sox family of transcription fac-
tors? 
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Notes 
 
1. The abbreviations used are: HMG, high mobility group; EC, embryonal carcinoma; FGF, fibro-
blast growth factor; CAT, chloramphenicol acetyltransferase; PCR, polymerase chain reaction; 
CMV, cytomegalovirus; ECF, enhanced chemifluorescence; gal, galactosidase; GFP, green fluo-
rescent protein; DBD, DNA-binding domain; POU, pit, oct, and unc. 
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